Response Genetics (RGDX) Reports Q1 Loss of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Response Genetics, Inc. Announces First Quarter 2015 Financial Results
May 14, 2015 7:00 AM EDTLOS ANGELES, May 14, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the first quarter ended March 31, 2015.
Total revenue for the first quarter ended March 31, 2015 was $3.8 million compared to $3.9 million for the quarter ended March 31, 2014. The Company's ResponseDX® revenue was $3.3 million which was consistent with the quarter ended March 31, 2014. The Company's pharmaceutical client revenue, which varies significantly on a quarterly basis by its nature and... More
